Nicotinic acid/laropiprant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemia

Archives of Medical Science

Volumn 10, Issue 3, 2014, Pages 439-444

  Kei, Anastazia ^a   Elisaf, Moses ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Mean platelet volume; Niacin; Nicotinic acid; Platelet distribution width; Platelets

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADD ON THERAPY; ADULT; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIETARY INTAKE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIFESTYLE; MALE; THROMBOCYTE COUNT; THROMBOCYTE VOLUME;

EID: 84903612796     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2014.43738     Document Type: Article

References (33)

1. Slavka G, Perkmann T, Haslacher H, et al. Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease. Arterioscler Thromb Vasc Biol 2011; 31: 1215-8.
2. Jindal S, Gupta S, Gupta R, et al. Platelet indices in diabetes mellitus: indicators of diabetic microvascular complications. Hematology 2011; 16: 86-9.
3. Pikija S, Cvetko D, Hajduk M, Trkulja V. Higher mean platelet volume determined shortly after the symptom onset in acute ischemic stroke patients is associated with a larger infarct volume on CT brain scans and with worse clinical outcome. Clin Neurol Neurosurg 2009; 111: 568-73.
4. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005; 258: 94-114.
5. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-92.
6. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-55.
7. Florentin M, Liberopoulos EN, Kei A, Mikhailidis DP, Elisaf MS. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation. Curr Vasc Pharmacol 2011; 9: 385-400.
8. NIASPAN [package insert]. North Chicago, IL: Abbott Laboratories http://www.rxabbott.com/pdf/niaspan.pdfNIASPAN
9. TREDAPTIVE product overview. [Online] [cited 2008]. Available from: http://www.ema.europa.eu/humandocs/Humans/EPAR/tredaptive/tredaptive.htm.
10. Expert Panel on Detection Evaluation And Treatment of High Blood Cholesterol In Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
11. Thompson CB, Jakubowski JA, Quinn PG, Deykin D, Valeri CR. Platelet size and age determine platelet function independently. Blood 1984; 63: 1372-5.
12. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-94.
13. Wang RT, Li Y, Zhu XY, Zhang YN. Increased mean platelet volume is associated with arterial stiffness. Platelets 2011; 22: 447-51. .
14. Lippi G, Filippozzi L, Salvagno GL, et al. Increased mean platelet volume in patients with acute coronary syndromes. Arch Pathol Lab Med 2009; 133: 1441-3.
15. Ha SI, Choi DH, Ki YJ, et al. Stroke prediction using mean platelet volume in patients with atrial fibrillation. Platelets 2011; 22: 408-14.
16. Yarlioglues M, Kaya MG, Ardic I, et al. Relationship between mean platelet volume levels and subclinical target organ damage in newly diagnosed hypertensive patients. Blood Press 2011; 20: 92-7.
17. Pereg D, Berlin T, Mosseri M. Mean platelet volume on admission correlates with impaired response to thrombolysis in patients with ST-elevation myocardial infarction. Platelets 2010; 21: 117-21.
18. Kandis H, Ozhan H, Ordu S, et al. The prognostic value of mean platelet volume in decompensated heart failure. Emerg Med J 2011; 28: 575-8.
19. Tavil Y, Sen N, Yazici H, et al. Coronary heart disease is associated with mean platelet volume in type 2 diabetic patients. Platelets 2010; 21: 368-72.
20. Jagroop IA, Tsiara S, Mikhailidis DP. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets 2003; 14: 335-6.
21. Coban E, Afacan B. The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment. Platelets 2008; 19: 111-4.
22. Muscari A, De Pascalis S, Cenni A, et al. Determinants of mean platelet volume (MPV) in an elderly population: relevance of body fat, blood glucose and ischaemic electrocardiographic changes. Thromb Haemost 2008; 99: 1079-84.
23. Jurcut C, Jurcut R, Caraiola S, et al. Platelet histogram indices and cardiovascular disease in patients with rheumatoid arthritis. Rom J Intern Med 2010; 48: 51-5.
24. De Luca G, Venegoni L, Iorio S, et al. Platelet distribution width and the extent of coronary artery disease: results from a large prospective study. Platelets 2010; 21: 508-14.
25. Lauring B, Dishy V, Luo WL, et al. Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. J Clin Pharmacol 2009; 49: 1426-35.
26. Lai E, Schwartz JI, Dallob A, et al. Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects. Platelets 2010; 21: 191-8.
27. Dallob A, Luo WL, Luk JM, et al. The effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin. Platelets 2011; 22: 495-503.
28. Kei A, Liberopoulos EN, Elisaf MS. What restricts the clinical use of nicotinic acid? Curr Vasc Pharmacol 2011; 9: 521-30.
29. Arslan N, Makay B. Mean platelet volume in obese adolescents with nonalcoholic fatty liver disease. J Pediatr Endocrinol Metab 2010; 23: 807-13.
30. Kei A, Elisaf M, Moutzouri E, Tsiara S, Liberopoulos E. Add-on-statin extended release nicotinic acid/laropiprant but not switch to high-dose rosuvastatin lowers blood pressure: an open-label randomized study. Int J Hypertens 2011; 2011: 830434.
31. AIM-HIGH investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. Am Heart J 2011; 161: 538-43.
32. NIH pulls plug on AIM-HIGH trial with niacin http://www.theheart.org/ article/1231453.do?utm-campaign= newsletter&utm-medium=email&utm- source=20110601-topTen-mai [cited 27 May, 2011].
33. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34: 1279-91.